Improving Islet Transplantation Outcomes With Gastrin

  • STATUS
    Recruiting
  • End date
    Feb 1, 2026
  • participants needed
    20
  • sponsor
    City of Hope Medical Center
Updated on 15 March 2022
diabetes
insulin
fasting
glucagon
hypoglycemia
c-peptide
hypoglycemic episodes
ketoacidosis
diabetic ketoacidosis
fasting c-peptide level
hypoglycaemia unawareness
pancreatic islet transplantation
hypoglycemic drugs

Summary

This clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control.

This study involves two investigational (experimental) products not yet approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease:

  1. Human allogenic islet cells (islet cells from a deceased, unrelated human donor)
  2. Gastrin-17 (Gastrin) - a hormone secreted by the gut

Description

Islet cell transplantation involves transplanting the cells that make insulin from a pancreas of deceased organ donor to a patient with diabetes. Because there is a limited supply of donor islet cells available, this study is testing whether Gastrin injections can help make a fewer number of transplanted islets work better.

Gastrin is a natural gut hormone that is present in the pancreas during its development in the embryo but not after birth, and is believed to participate in the formation of the normal pancreas. Several studies have tried to use gastrin to help grow insulin making islet cells in laboratory experiments or after transplanting islets in laboratory animals. In early clinical trials, diabetic patients treated with gastrin and other growth factors required less insulin after 4 weeks of gastrin treatment and the effect lasted more than 12 weeks after stopping treatment, suggesting that gastrin may have increased the number of cells that make insulin.

This study will evaluate whether taking Gastrin injections following a single islet transplantation is safe, improves how well the islet transplant works and/or helps increase the number of insulin-making cells in the islets.

Qualified participants will receive treatment with a single islet transplant, followed by two rounds of gastrin treatment (twice daily injections for 30 days) just after transplant and again 6 months later. Study participants will also take anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support their health and/or the health of the transplanted islets. Participants will need to return to City of Hope in Duarte, CA for frequent follow-up visits for one year after transplant.

Details
Condition Diabetes Mellitus, Type 1
Treatment Allogenic Human Islet Cells, Gastrin 17
Clinical Study IdentifierNCT03746769
SponsorCity of Hope Medical Center
Last Modified on15 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18-68 years
Type 1 diabetes mellitus (documented with fasting C-peptide level of </= 0.2 ng/ml before and </= 0.3 ng/ml after IV administration of 1 mg of glucagon) for at least 5 years
Unstable blood glucose characterized by
Frequent hypoglycemia (blood glucose less than or equal to 54 mg/dl more than
once per week)
and/or- Hypoglycemia unawareness (Clarke score of 4 or more)
and/or- One or more severe hypoglycemic episodes in 12 months preceding enrollment
and/or- Erratic blood glucose levels that interfere with daily activities
and/or- One or more hospital visits for diabetic ketoacidosis in the 12 months preceding enrollment
Ability and willingness to comply with post-transplant regimen, including immunosuppression, use of reliable contraception, frequent clinic visits, testing and maintaining detailed logs of blood glucose levels, insulin doses and medications, and completing detailed follow-up studies
Ability to give informed consent

Exclusion Criteria

BMI > 33
Insulin requirements > 1.0 units/kg/day
Significant kidney disease (estimated GFR from serum creatinine measurement <65 ml/min, random spot urine microalbumin to creatinine ratio >300mg albumin/g creatinine)
Significant hepatobiliary disease, including elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST (any elevation of these enzymes will be determined), bilirubin not within normal limits, albumin < 3.5 g/dl, liver masses, portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e. gallstones)
Significant cardiovascular disease, including non-correctable coronary artery disease with ejection fraction < 50% and/or recent myocardial infarction (within last 12 months); or extensive peripheral vascular disease not correctable by surgery
Evidence of active proliferative retinopathy
Hypertension( >/= 140/90) despite appropriate treatment
Hyperlipidemia (total cholesterol > 260 mg/dl, LDL > 160 mg/dl, and/or triglycerides > 300 mg/dl) despite appropriate treatment
Anemia (Hgb < 11 g/dl) or other hematologic disorders that require medical attention
WBC <3,000/ul
Increased risk of bleeding (platelet count < 120,000 cells/ul; INR > 1.5), other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy (i.e. heparin or warfarin)
Recent unresolved acute infection (except for mild skin infection or nail fungal infection), or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or syphilis (RPR)
EBV IgG negative
Any history of malignancy, except completely resected squamous or basal cell skin cancer or in situ cancer of the cervix
Evidence of active peptic ulcer disease
History of gastric bypass
Recent history of non-adherence to recommended medical therapy
Psychiatric illness that is untreated, or likely to interfere significantly with study compliance despite treatment
Previous organ/tissue transplant
Administration of live attenuated vaccines within 60 days of enrollment
Presence of a chronic disease that must be chronically treated with contraindicated medications
Use of investigational agents within four weeks of enrollment
Active alcohol or substance abuse, including cigarette smoking (must be abstinent for > 3 months)
Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures (i.e., tubal ligation, two barrier methods, abstinence) for the duration of study treatment and for as long as they are on immunosuppressive medication, and women presently breastfeeding
Individuals without health insurance covering the cost of immunosuppression and clinical and laboratory follow-up after completion of the study
Any medical condition that in the opinion of the investigator will interfere with safe participation in the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note